- Home
- CNTB vs ALVR Comparison
CNTB vs ALVR Comparison
Compare CNTB & ALVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTB
- ALVR
- Stock Information
- Founded
- CNTB 2012
- ALVR 2013
- Country
- CNTB United States
- ALVR United States
- Employees
- CNTB N/A
- ALVR N/A
- Industry
- CNTB Biotechnology: Pharmaceutical Preparations
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CNTB Health Care
- ALVR Health Care
- Exchange
- CNTB Nasdaq
- ALVR Nasdaq
- Market Cap
- CNTB 55.2M
- ALVR 48.8M
- IPO Year
- CNTB 2021
- ALVR 2020
- Fundamental
- Price
- CNTB $0.81
- ALVR $9.49
- Analyst Decision
- CNTB Strong Buy
- ALVR
- Analyst Count
- CNTB 1
- ALVR 0
- Target Price
- CNTB $8.00
- ALVR N/A
- AVG Volume (30 Days)
- CNTB 18.3K
- ALVR 8.8K
- Earning Date
- CNTB 04-15-2025
- ALVR 03-18-2025
- Dividend Yield
- CNTB N/A
- ALVR N/A
- EPS Growth
- CNTB N/A
- ALVR N/A
- EPS
- CNTB N/A
- ALVR N/A
- Revenue
- CNTB $24,116,000.00
- ALVR N/A
- Revenue This Year
- CNTB N/A
- ALVR N/A
- Revenue Next Year
- CNTB $62.09
- ALVR N/A
- P/E Ratio
- CNTB N/A
- ALVR N/A
- Revenue Growth
- CNTB N/A
- ALVR N/A
- 52 Week Low
- CNTB $0.77
- ALVR $7.96
- 52 Week High
- CNTB $2.66
- ALVR $24.15
- Technical
- Relative Strength Index (RSI)
- CNTB 39.94
- ALVR 45.47
- Support Level
- CNTB $0.79
- ALVR $9.45
- Resistance Level
- CNTB $0.91
- ALVR $10.15
- Average True Range (ATR)
- CNTB 0.08
- ALVR 0.54
- MACD
- CNTB -0.00
- ALVR -0.02
- Stochastic Oscillator
- CNTB 26.15
- ALVR 23.87
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.